SpectaCell raises €6M seed for cell therapy analytics
Four founders out of imec, VIB and Ghent University raised €6 million to measure how single cells respond to therapy - with every cheque from Benelux institutional capital.
Also see more funding coverage: /funding/
Founded 2026 · Ghent, Belgium
SpectaCell, a Ghent-based spin-off of imec, VIB and Ghent University, has raised a €6 million seed round led by imec.xpand to commercialise its label-free single-cell analysis platform for cell therapy and immunotherapy development.
Cell therapies are the hardest medicines we make – and the hardest to measure. A European seed round built entirely from institutional and regional capital just bet €6 million that the measuring is where the value sits.
Below, I lay out the round, the platform behind it, the market it sells into and what it says about how Flanders builds deep-tech companies.
A seed round where every cheque is institutional
SpectaCell announced its €6 million seed round on 8 October 2026, led by imec.xpand, the deep-tech venture fund built around the imec research institute. PMV’s Flanders Future Tech Fund, the Dutch regional investor InnovationQuarter Capital, the inter-university fund Qbic and VIB joined the round.
Look at that list again: a research institute’s venture arm, the Flemish region’s tech fund, a South Holland public investor, a university fund and VIB itself – the institute SpectaCell spun out of. Not one classic private VC in sight, and that is not a weakness here; it is how Benelux deep tech gets built.
The money goes to “further development and commercialisation of the platform with pharmaceutical and biotechnology partners”, per the company’s announcement of 8 October 2026.
Four founders, one chip, no fluorescent labels
SpectaCell was founded in 2026 as a spin-off of imec, VIB and Ghent University by Tony Montoye (CEO), Veronique De Vroey, Mathieu Rabaey and Jan Van de Velde. Per the announcement, the founding team’s CVs run through VIB, Biocartis, CellCarta, Trinean, Johnson & Johnson and Galapagos – the bench strength of Flemish life-science tooling.
The platform combines chip-based imaging with data analysis to track large numbers of individual live cells over time, without the fluorescent labels that standard methods need and that disturb the very cells being measured. A cartridge-based instrument in development aims to return results in hours rather than days, for use in cell therapies and T-cell engagers.
“Breakthrough medicines need breakthrough tools,” said Montoye in the announcement. “Researchers need to know much earlier which candidates deserve further investment and why.”
A $3.81bn tools market compounding at 14.7%
The segment SpectaCell sells into is measurable: the global single-cell analysis market stood at an estimated $3.81 billion in 2025 and is projected to reach $7.56 billion by 2030, a 14.7% CAGR (MarketsandMarkets, May 2025). Tools that make cell therapy development faster ride both that curve and the therapies’ own growth.
For scale against this week’s European health rounds in our records: Rivercell raised a €22 million seed led by HV Capital to model cells in silico, and RougeTx raised a $58 million Series A for a rare-disease therapeutic. A €6 million tools seed is the standard Benelux entry ticket; the asset rounds run four to ten times larger.
The good news is that tools companies do not carry clinical-trial risk. They sell to everyone running the trials – which is exactly where a platform priced in hours rather than days earns its keep.
Institutes building their own picks and shovels
What we are seeing in this round is a pattern Flanders has quietly perfected: the research institute does not just license its IP out, it incorporates the company, staffs it from its own alumni and funds it through a captive vehicle. imec.xpand led, VIB invested in its own spin-off, and the regional funds filled the table.
So why does a €6 million seed deserve this much attention? Because the chain that produced it is repeatable. Imagine if every major European research institute ran the same playbook – a fund, a foundry and an alumni bench. Flanders is showing what the output looks like, one spin-off at a time; the full ledger is in our fundraising data.
“We are convinced that SpectaCell can become essential to how new medicines are selected, developed and produced,” said Benoit Devogelaere, partner at imec.xpand, in the announcement. For the lead investor, this is a bet on measurement as the choke point of cell therapy – what to watch next is whether the cartridge instrument lands named pharmaceutical partners before a Series A.
The therapies will get the headlines; the tools will decide who ships them. Watch Ghent.
